Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.

Name: Kaimen Rigor review — Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.
Item: Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.
Rating: 100
Author: Alpha1

Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, Morrow AJ, Sykes R, Gildea P, Petty M, Brogan R, Carrick D, Collison D, Eteiba H, Ghattas A, Good R, Joshi F, Lindsay M, McCartney P, McGowan J, McGeoch R, Robertson K, Rocchiccioli P, Shaukat A, Watkins S, Kellman P, McConnachie A, Berry C

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.5★ (Weak), 0 critical, 3 high issues for “Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.

Read full text (PMC)

DOI

10.1038/s41591-025-04044-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/e9991f18-04a7-4a26-ade8-9a59ffaaeaa9" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/e9991f18-04a7-4a26-ade8-9a59ffaaeaa9/badge" alt="Kaimen Rigor review — 2.5★ (Weak), 0 critical, 3 high issues for “Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

20253e18eb693f599d57cd48def96b441ad28cd8af08846809abd64fa34f24fd

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.

Paper source

Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on the Seattle Angina Questionnaire (SAQ) summary score, a patient-reported outcome measure of angina burden and quality of life. While SAQ is a validated clinical scale, the paper does not demonstrate target engagement at the tested dose (e.g., PK/PD or dose-exposure relationship) nor cite validated evidence linking SAQ to hard clinical outcomes. The claim of improved angina and quality of life rests on this surrogate endpoint without establishing a direct link to clinical outcomes.
“The primary outcome of the randomized trial was the Seattle Angina Questionnaire (SAQ) summary score at 12 months after randomization.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect size is a mean difference of 20.9 points on the SAQ summary score (95% CI 15.8–26.0). While this is statistically significant, the manuscript does not anchor this difference to a minimal clinically important difference (MCID) or provide evidence that this magnitude is clinically meaningful. The effect size is presented as a positive result without explicit clinical meaningfulness.
“adjusted mean difference: 20.9 (95% confidence interval: 15.8–26.0)”
Find in source
03Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT04805814 was first submitted to ClinicalTrials.gov on 2021-03-09, after the registered study start date of 2021-02-09. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT04805814
reviewer’s wording

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 103AuthenticityData authenticity concerns 04DisclosureNone found 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomized controlled trial. The study design is rigorous with proper randomization, blinding, and a prespecified analysis plan. Minor reporting issues include a retrospective registration gap, a rounding discrepancy in the abstract, and a formatting error in the data availability statement.

Both reviewers classified the study as interventional, which is adopted. The evaluation covers all eight dimensions; no dimensions were excluded as not applicable. The reviewers agreed on all dimensions; no divergence required resolution.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst medium

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites multiple prior studies and guidelines establishing the diagnostic challenge of ANOCA and the potential of functional testing. The rationale for using CMR to endotype patients is clearly linked to the hypothesis that CMR-guided management improves diagnosis and symptoms. Limitations of prior research (e.g., lack of randomized trials for CMR) are explicitly addressed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the premise to the study objectives.

Evidence

“The Coronary Microvascular Angina (CorMicA) trial demonstrated that coronary function testing during invasive management of suspected ANOCA is associated with improvements in symptoms, health-related quality of life and health economics . These results were recently validated in the ILIAS ANOCA trial .”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 3]

“Among patients with chest pain without obstructive coronary artery disease defined by invasive angiography, we aimed to assess whether re-evaluation of the endotype informed by stress CMR imaging ... affected the final diagnosis, angina burden and health-related quality of life.”

“Cardiovascular magnetic resonance (CMR) , and nuclear stress positron emission tomography quantify myocardial blood flow and may be used to diagnose coronary microvascular dysfunction, but evidence of clinical utility from randomized trials is lacking.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the premise to the study objectives.

Evidence

Introduction ¶1Find in source

Introduction ¶3Find in source

“We hypothesized that coronary vasomotor endotypes are prevalent in a post-angiography population with no obstructive coronary arteries, and, compared to angiography-guided management, CMR-guided management changes the diagnosis and improves symptoms and health-related quality of life.”

Introduction ¶3Find in source

Randomization used a minimization algorithm with a random element, and the unit is the participant. Blinding of participants, clinicians, and outcome assessors is described, with effectiveness assessed. A sample size calculation is provided. Inclusion/exclusion criteria are explicitly listed. The analysis population (ITT) and missing data handling are defined. The control group (angiography-guided) serves as the comparator.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Randomization was performed using a minimization algorithm with respect to study site, sex, prior myocardial infarction, evidence of coronary artery disease on angiography, diabetes and left ventricular systolic function (<55%, ≥55%). A small random element was included whereby two randomly selected participants in each block of 10 were allocated at random (one to each arm), to reduce predictability.”

Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.

Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting